Dr. Yazeed Sawalha

Claim this profile

Ohio State University Comprehensive Cancer Center

Studies Non-Hodgkin's Lymphoma
Studies Diffuse Large B-Cell Lymphoma
4 reported clinical trials
10 drugs studied

Area of expertise

1

Non-Hodgkin's Lymphoma

Yazeed Sawalha has run 3 trials for Non-Hodgkin's Lymphoma. Some of their research focus areas include:

MYC positive
BCL2 positive
BCL6 positive
2

Diffuse Large B-Cell Lymphoma

Yazeed Sawalha has run 3 trials for Diffuse Large B-Cell Lymphoma. Some of their research focus areas include:

MYC positive
BCL2 positive
BCL6 positive

Affiliated Hospitals

Image of trial facility.

Ohio State University Comprehensive Cancer Center

Clinical Trials Yazeed Sawalha is currently running

Image of trial facility.

Rituximab vs Mosunetuzumab

for Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

Recruiting

2 awards

Phase 3

13 criteria

Image of trial facility.

Zanubrutinib + R-CHOP

for Diffuse Large B-Cell Lymphoma

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunotherapy regimen for DLBCL and is considered the standard-of-care treatment for patients with DLBCL. Three of the drugs in R-CHOP (cyclophosphamide, doxorubicin and vincristine) are chemotherapy drugs. Rituximab is a type of immunotherapy and prednisone is a type of steroids.

Recruiting

1 award

Phase 1

More about Yazeed Sawalha

Clinical Trial Related

1 year of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Yazeed Sawalha has experience with

  • Rituximab
  • Cyclophosphamide
  • Prednisone
  • Vincristine Sulfate
  • Epcoritamab
  • Ibrutinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Yazeed Sawalha specialize in?

Is Yazeed Sawalha currently recruiting for clinical trials?

Are there any treatments that Yazeed Sawalha has studied deeply?

What is the best way to schedule an appointment with Yazeed Sawalha?

What is the office address of Yazeed Sawalha?

Is there any support for travel costs?